Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pozanicline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 known ✓ | P17787 | 2/20 | 1.00 |
| ▸ | CHRNA4 known ✓ | P43681 | 2/20 | 1.00 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.73 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.73 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.56 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pozanicline SCHEMBL194037 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Pozanicline SCHEMBL1538473 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Pozanicline SCHEMBL7367252 | 1.00 | CHRNB2 (1.00) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Pozanicline SCHEMBL29711154 | 0.99 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Pozanicline SCHEMBL7838537 | 0.99 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Pozanicline SCHEMBL5139644 | 0.99 | CHRNB2 (0.97) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL7373407 | 0.89 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| SCHEMBL905231 | 0.89 | CHRNB2 (0.81) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Hydrochloric Acid SCHEMBL7450656 | 0.88 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 | |
| Hydrochloric Acid SCHEMBL7415362 | 0.88 | CHRNB2 (0.78) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 144 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-119732526-A | Nicotine substitution compound, atomized liquid composition, preparation method of atomized liquid composition and electronic atomization device | 深圳梵活生命科学股份有限公司 | 2025-04-01 | — | — | CN | claimed |
| WO-2025040605-A1 | OPHTHALMOLOGICAL COMPOSITION CONTAINING AT LEAST ONE NICOTINIC ACETYLCHOLINE RECEPTOR MODULATOR FOR TOPICAL ADMINISTRATION TO THE EYE FOR PREVENTING OR TREATING INFLAMMATION OF THE EYE | URSAPHARM ARZNEIMITTEL GMBH (DE) | 2025-02-27 | — | — | WO | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| WO-2024191125-A1 | METHOD FOR ACTIVATING ENDOGENOUS NEURAL STEM CELLS THROUGH LOW-INTENSITY FOCUSED ULTRASOUND TREATMENT | 연세대학교 산학협력단 | 2024-09-19 | — | — | WO | claimed |
| WO-2023212244-A1 | METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS | TESSELLATE THERAPEUTICS, INC. (US) | 2023-11-02 | — | — | WO | claimed |
| CN-109563089-B | Compounds that promote normal processing of APP | 巴克老年研究所 | 2023-06-16 | — | — | CN | claimed |
| US-20220305006-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-09-29 | — | — | US | claimed |
| EP-3969444-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS | The Regents of the University of California (US) | 2022-03-23 | — | — | EP | claimed |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2026-05-26 | — | — | US | disclosed |
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | ALTO NEUROSCIENCE INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4126858-B1 | DIHYDRO-2-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2026-03-18 | — | — | EP | disclosed |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | KARUNA THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | NKMAX CO LTD (KR) | 2026-02-19 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220062378-A1 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | UNIVERSITY OF COPENHAGEN (DK) | 2022-03-03 | — | — | US | disclosed |
| US-20220062252-A1 | CYCLOOXYGENASE INHIBITOR AND CALCIUM CHANNEL ANTAGONIST COMPOSITIONS AND METHODS FOR USE IN UROLOGICAL PROCEDURES | OMEROS CORP (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220041684-A1 | ENGINEERED PLATELETS FOR TARGETED DELIVERY OF A THERAPEUTIC AGENT | JPV01 LTD. (GB) | 2022-02-10 | — | — | US | disclosed |
| CN-114010641-A | Methods for treating neurological disorders | 爱普制药有限责任公司 | 2022-02-08 | — | — | CN | disclosed |
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | MERCK SHARP & DOHME CORP. (US) | 2022-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137689-A1 | INTEGRATION OF MOLECULAR MECHANISMS IN THE STRIATUM AS A COMBINATION DRUG STRATEGY FOR THE TREATMENT OF PSYCHIATRIC AND NEUROLOGICAL DISORDERS IN WHICH ANHEDONIA OR MOTIVATION-RELATED DYSFUNCTION EXISTS | CHRNA5, CHRNA2, CHRNA4 | CHRNB2 11/4885CHRNA4 3/4885CHRNB4 15/4885 |
| US-20220305006-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS | PSEN2, BACE1, PSEN1 | CHRNB2 200/4885CHRNA4 525/4885CHRNB4 437/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | CHRNB2 64/4885CHRNA4 91/4885CHRNB4 104/4885 |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | GABRA5, GABRA1, GABRB1 | CHRNB2 91/4885CHRNA4 29/4885CHRNB4 67/4885 |
| US-11230556-B2 | 6,5-fused heteroaryl piperidine ether allosteric modulators of the M4 muscarinic acetylcholine receptor | CHRM5, CHRM4, CHRM2 | CHRNB2 22/4885CHRNA4 8/4885CHRNB4 17/4885 |
| US-20260048083-A1 | METHOD OF TREATING ALZHEIMER'S DISEASE WITH EXPANDED NATURAL KILLER CELLS | IL2, PBK, IL2RA | CHRNB2 165/4885CHRNA4 413/4885CHRNB4 541/4885 |
| US-20260055116-A1 | SUBSTITUTED TETRAHYDROPYRROLO-PYRIDINONE COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | CHRM3, CHRM2, CHRM1 | CHRNB2 26/4885CHRNA4 19/4885CHRNB4 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.